A Randomized, Open-Label, Comparative, Multi-Center Trial to Evaluate Contraceptive Efficacy, Cycle Control, Safety and Acceptability of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2) [estradiol/nomegestrol], Compared to a Monophasic COC Containing 3 mg Drospirenone (DRSP) and 30 µg Ethinyl Estradiol (EE) [ethinylestradiol/drospirenone]

Trial Profile

A Randomized, Open-Label, Comparative, Multi-Center Trial to Evaluate Contraceptive Efficacy, Cycle Control, Safety and Acceptability of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2) [estradiol/nomegestrol], Compared to a Monophasic COC Containing 3 mg Drospirenone (DRSP) and 30 µg Ethinyl Estradiol (EE) [ethinylestradiol/drospirenone]

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Estradiol/nomegestrol (Primary) ; Drospirenone/ethinylestradiol
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Acronyms Samba
  • Sponsors Organon
  • Most Recent Events

    • 20 Dec 2016 Results of pooled analysis of two studies (RUMBA and Samba) published in the Contraception
    • 23 Jun 2012 Moos Menstrual Distress Questionnaire results presented at the 12th Congress of the European Society of Contraception.
    • 01 Dec 2011 Results published in the European Journal of Contraception and Reproductive Health Care.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top